Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Community Health (CYH) and Bausch Health Companies (BHC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Praxis Precision Medicines (PRAX – Research Report), Community Health (CYH – Research Report) and Bausch Health Companies (BHC – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Praxis Precision Medicines (PRAX)
Truist Financial analyst Joon Lee maintained a Buy rating on Praxis Precision Medicines today. The company’s shares closed last Wednesday at $328.93.
According to TipRanks.com, Lee is a 5-star analyst with an average return of
Praxis Precision Medicines has an analyst consensus of Strong Buy, with a price target consensus of $596.21, an 81.1% upside from current levels. In a report issued on February 4, Needham also maintained a Buy rating on the stock with a $510.00 price target.
See the top stocks recommended by analysts >>
Community Health (CYH)
Truist Financial analyst David S Macdonald maintained a Hold rating on Community Health today. The company’s shares closed last Wednesday at $3.34.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
Currently, the analyst consensus on Community Health is a Hold with an average price target of $3.50, a 3.2% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $3.50 price target.
Bausch Health Companies (BHC)
In a report released today, Les Sulewski from Truist Financial maintained a Hold rating on Bausch Health Companies. The company’s shares closed last Wednesday at $6.19.
According to TipRanks.com, Sulewski is a 4-star analyst with an average return of
Bausch Health Companies has an analyst consensus of Hold, with a price target consensus of $7.67, representing a 28.0% upside. In a report released today, RBC Capital also maintained a Hold rating on the stock with a $10.00 price target.
